SU 11248

Known as: SU 011248, SU011248, SU11248 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
Herein we report that the VEGFR/PDGFR kinase inhibitor sunitinib/SU11248 can accelerate metastatic tumor growth and decrease… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
PURPOSE Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor approved for advanced renal cell carcinoma and… (More)
  • table 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2007
Highly Cited
2007
PURPOSE There is an unmet need for noninvasive markers to measure the biological effects of targeted agents, particularly those… (More)
  • figure 2
  • figure 1
  • figure 4
  • figure 3
  • figure 6
Is this relevant?
Highly Cited
2007
Highly Cited
2007
UNLABELLED Liver cirrhosis is a very complex disease in which several pathological processes such as inflammation, fibrosis, and… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
PURPOSE Renal cell carcinoma (RCC) is characterized by loss of von Hippel Lindau tumor suppressor gene activity, resulting in… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
CONTEXT The oncogenic RET/PTC tyrosine kinase causes papillary thyroid cancer (PTC). The use of inhibitors specific for RET/PTC… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
PURPOSE A transgenic mouse model has revealed parameters of the angiogenic switch during multistep tumorigenesis of pancreatic… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Fifteen patients with refractory AML were treated in a phase 1 study with SU11248, an oral kinase inhibitor of fms-like tyrosine… (More)
  • table 1
  • table 2
  • table 3
  • figure 2
  • figure 1
Is this relevant?
Highly Cited
2003
Highly Cited
2003
FLT3 (fms-related tyrosine kinase/Flk2/Stk-2) is a receptor tyrosine kinase (RTK) primarily expressed on hematopoietic cells. In… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2003
Highly Cited
2003
One challenging aspect in the clinical development of molecularly targeted therapies, which represent a new and promising… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?